vs

Side-by-side financial comparison of CORE MOLDING TECHNOLOGIES INC (CMT) and PROCEPT BioRobotics Corp (PRCT). Click either name above to swap in a different company.

PROCEPT BioRobotics Corp is the larger business by last-quarter revenue ($83.1M vs $74.7M, roughly 1.1× CORE MOLDING TECHNOLOGIES INC). On growth, PROCEPT BioRobotics Corp posted the faster year-over-year revenue change (20.2% vs 19.5%). Over the past eight quarters, PROCEPT BioRobotics Corp's revenue compounded faster (24.8% CAGR vs -2.2%).

Core Molding Technologies, Inc. was founded in 1988 and now based in Columbus, Ohio. The company manufactures sheet molding compounds (SMC), and molds fiberglass reinforced plastics. It occupies over 1,000,000 square feet of manufacturing space and its main subsidiaries are in Matamoros, Mexico, Gaffney, South Carolina, and Cincinnati, Ohio. In 2011, Core Molding Technologies formed Core Specialty Composites, LLC.

PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.

CMT vs PRCT — Head-to-Head

Bigger by revenue
PRCT
PRCT
1.1× larger
PRCT
$83.1M
$74.7M
CMT
Growing faster (revenue YoY)
PRCT
PRCT
+0.7% gap
PRCT
20.2%
19.5%
CMT
Faster 2-yr revenue CAGR
PRCT
PRCT
Annualised
PRCT
24.8%
-2.2%
CMT

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CMT
CMT
PRCT
PRCT
Revenue
$74.7M
$83.1M
Net Profit
$-31.6M
Gross Margin
15.2%
64.9%
Operating Margin
4.8%
-4.1%
Net Margin
-38.1%
Revenue YoY
19.5%
20.2%
Net Profit YoY
-27.9%
EPS (diluted)
$0.35
$-0.56

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CMT
CMT
PRCT
PRCT
Q1 26
$83.1M
Q4 25
$74.7M
$76.4M
Q3 25
$58.4M
$83.3M
Q2 25
$79.2M
$79.2M
Q1 25
$61.4M
$69.2M
Q4 24
$62.5M
$68.2M
Q3 24
$73.0M
$58.4M
Q2 24
$88.7M
$53.4M
Net Profit
CMT
CMT
PRCT
PRCT
Q1 26
$-31.6M
Q4 25
$-29.8M
Q3 25
$1.9M
$-21.4M
Q2 25
$4.1M
$-19.6M
Q1 25
$2.2M
$-24.7M
Q4 24
$-18.9M
Q3 24
$3.2M
$-21.0M
Q2 24
$6.4M
$-25.6M
Gross Margin
CMT
CMT
PRCT
PRCT
Q1 26
64.9%
Q4 25
15.2%
60.6%
Q3 25
17.4%
64.8%
Q2 25
18.1%
65.4%
Q1 25
19.2%
63.9%
Q4 24
15.8%
64.0%
Q3 24
16.9%
63.2%
Q2 24
20.0%
59.0%
Operating Margin
CMT
CMT
PRCT
PRCT
Q1 26
-4.1%
Q4 25
4.8%
-40.6%
Q3 25
4.4%
-27.8%
Q2 25
6.6%
-28.0%
Q1 25
4.6%
-39.7%
Q4 24
1.4%
-28.9%
Q3 24
4.9%
-38.4%
Q2 24
8.4%
-50.3%
Net Margin
CMT
CMT
PRCT
PRCT
Q1 26
-38.1%
Q4 25
-39.1%
Q3 25
3.2%
-25.7%
Q2 25
5.1%
-24.7%
Q1 25
3.6%
-35.8%
Q4 24
-27.6%
Q3 24
4.3%
-35.9%
Q2 24
7.2%
-48.0%
EPS (diluted)
CMT
CMT
PRCT
PRCT
Q1 26
$-0.56
Q4 25
$0.35
$-0.54
Q3 25
$0.22
$-0.38
Q2 25
$0.47
$-0.35
Q1 25
$0.25
$-0.45
Q4 24
$-0.01
$-0.34
Q3 24
$0.36
$-0.40
Q2 24
$0.73
$-0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CMT
CMT
PRCT
PRCT
Cash + ST InvestmentsLiquidity on hand
$38.1M
$245.6M
Total DebtLower is stronger
$17.6M
$51.7M
Stockholders' EquityBook value
$158.2M
$347.7M
Total Assets
$228.1M
$487.1M
Debt / EquityLower = less leverage
0.11×
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CMT
CMT
PRCT
PRCT
Q1 26
$245.6M
Q4 25
$38.1M
$286.5M
Q3 25
$42.4M
$294.3M
Q2 25
$43.2M
$302.7M
Q1 25
$44.5M
$316.2M
Q4 24
$41.8M
$333.7M
Q3 24
$42.3M
$196.8M
Q2 24
$37.8M
$214.1M
Total Debt
CMT
CMT
PRCT
PRCT
Q1 26
$51.7M
Q4 25
$17.6M
$51.6M
Q3 25
$18.2M
$51.6M
Q2 25
$18.8M
$51.5M
Q1 25
$19.2M
$51.5M
Q4 24
$19.7M
$51.5M
Q3 24
$20.2M
$51.4M
Q2 24
$20.6M
$51.4M
Stockholders' Equity
CMT
CMT
PRCT
PRCT
Q1 26
$347.7M
Q4 25
$158.2M
$365.9M
Q3 25
$155.4M
$380.3M
Q2 25
$153.5M
$385.8M
Q1 25
$149.9M
$389.2M
Q4 24
$147.4M
$402.2M
Q3 24
$147.8M
$241.2M
Q2 24
$147.5M
$251.8M
Total Assets
CMT
CMT
PRCT
PRCT
Q1 26
$487.1M
Q4 25
$228.1M
$508.1M
Q3 25
$219.7M
$511.5M
Q2 25
$219.9M
$513.1M
Q1 25
$223.6M
$519.4M
Q4 24
$209.6M
$534.0M
Q3 24
$220.7M
$374.1M
Q2 24
$225.7M
$374.4M
Debt / Equity
CMT
CMT
PRCT
PRCT
Q1 26
0.15×
Q4 25
0.11×
0.14×
Q3 25
0.12×
0.14×
Q2 25
0.12×
0.13×
Q1 25
0.13×
0.13×
Q4 24
0.13×
0.13×
Q3 24
0.14×
0.21×
Q2 24
0.14×
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CMT
CMT
PRCT
PRCT
Operating Cash FlowLast quarter
$5.0M
Free Cash FlowOCF − Capex
$-2.9M
FCF MarginFCF / Revenue
-3.9%
Capex IntensityCapex / Revenue
10.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CMT
CMT
PRCT
PRCT
Q1 26
Q4 25
$5.0M
$-10.3M
Q3 25
$4.6M
$-6.6M
Q2 25
$3.5M
$-15.0M
Q1 25
$6.1M
$-17.0M
Q4 24
$5.0M
$-32.4M
Q3 24
$9.2M
$-18.8M
Q2 24
$15.9M
$-15.7M
Free Cash Flow
CMT
CMT
PRCT
PRCT
Q1 26
Q4 25
$-2.9M
$-12.2M
Q3 25
$-346.0K
$-9.5M
Q2 25
$880.0K
$-17.8M
Q1 25
$4.3M
$-18.8M
Q4 24
$509.0K
$-33.6M
Q3 24
$7.0M
$-19.0M
Q2 24
$13.0M
$-16.8M
FCF Margin
CMT
CMT
PRCT
PRCT
Q1 26
Q4 25
-3.9%
-15.9%
Q3 25
-0.6%
-11.4%
Q2 25
1.1%
-22.5%
Q1 25
7.0%
-27.2%
Q4 24
0.8%
-49.2%
Q3 24
9.6%
-32.6%
Q2 24
14.6%
-31.4%
Capex Intensity
CMT
CMT
PRCT
PRCT
Q1 26
Q4 25
10.7%
2.4%
Q3 25
8.4%
3.4%
Q2 25
3.3%
3.5%
Q1 25
2.9%
2.7%
Q4 24
7.2%
1.7%
Q3 24
3.1%
0.4%
Q2 24
3.3%
2.0%
Cash Conversion
CMT
CMT
PRCT
PRCT
Q1 26
Q4 25
Q3 25
2.44×
Q2 25
0.86×
Q1 25
2.79×
Q4 24
Q3 24
2.92×
Q2 24
2.47×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CMT
CMT

Segment breakdown not available.

PRCT
PRCT

Handpieces and other consumables$43.0M52%
System sales and rentals$23.4M28%
Other$11.1M13%
Service$5.6M7%

Related Comparisons